INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2026

Investments, All Other Investments [Abstract]

Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis

The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):


	March 31, 2026
	Cost		Unrealized Gains (Losses)		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities

Cash and cash equivalents, excluding money market accounts	$	50,961	$	—	$	—	$	50,961	$	50,961	$	—

Level 1:
Money market accounts	20,568		—		—		20,568		20,568		—
Government & agency securities	45,398		95		83		45,576		—		45,576

	65,966		95		83		66,144		20,568		45,576

Level 2:
Corporate bonds	51,513		(54)		382		51,841		—		51,841

Total	$	168,440	$	41	$	465	$	168,946	$	71,529	$	97,417


	December 31, 2025
	Cost		Unrealized Gains (Losses		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities

Cash and cash equivalents, excluding money market accounts	$	50,187	$	—	$	—	$	50,187	$	50,187	$	—

Level 1:
Money market accounts	39,116		—		—		39,116		39,116		—
Government & agency securities	23,247		111		80		23,438		—		23,438

	62,363		111		80		62,554		39,116		23,438

Level 2:
Corporate bonds	53,801		198		533		54,532		—		54,532

Total	$	166,351	$	309	$	613	$	167,273	$	89,303	$	77,970

Summary of Investment Gains

The gains related to the Company’s LifeMD investment for the three months ended March 31, 2026 and 2025 are summarized in the table below (in thousands):


	March 31, 2026		March 31, 2025

Net gains recognized during the period on equity securities	$	—	$	600
Less: Net gains recognized on equity securities sold	—		—
Unrealized gains recognized during the reporting period on equity securities still held at the reporting date	$	—	$	600